BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/27/2023 5:42:53 AM | Browse: 582 | Download: 1740
Publication Name World Journal of Gastroenterology
Manuscript ID 88715
Country China
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Letter to the Editor
Article Title Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1
Manuscript Source Unsolicited Manuscript
All Author List Yue-Hua Yin, Li-Xuan Sang and Bing Chang
ORCID
Author(s) ORCID Number
Yue-Hua Yin http://orcid.org/0009-0002-8560-9984
Li-Xuan Sang http://orcid.org/0000-0002-4562-0022
Bing Chang http://orcid.org/0000-0003-1965-5827
Funding Agency and Grant Number
Corresponding Author Bing Chang, N/A, Chief Physician, Postdoc, Professor, Department of Gastroenterology, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning Province, China. cb000216@163.com
Key Words Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Antidiabetic drugs; Glucagon-like peptide 1; Semaglutide
Core Tip Semaglutide is effective and safe for nonalcoholic fatty liver disease (NAFLD) but does not improve fibrosis. The treatment of NAFLD requires further combinations of drugs with different and complementary mechanisms of action.
Publish Date 2023-12-27 05:42
Citation Yin YH, Sang LX, Chang B. Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1. World J Gastroenterol 2023; 29(48): 6235-6238
URL https://www.wjgnet.com/1007-9327/full/v29/i48/6235.htm
DOI https://dx.doi.org/10.3748/wjg.v29.i48.6235
Full Article (PDF) WJG-29-6235-with-cover.pdf
Full Article (Word) WJG-29-6235.docx